IP Library Granted Patent US 12,342,843
Granted Patent B2
US 12,342,843 · App. 18/504,043 · Granted Jul 1, 2025

Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof

Inventors: Michael Bernard Miklus (Essex Junction, VT); Anja Monika Wittke (Munich, DE); Pedro Antonio Prieto (Columbus, OH); Cynthia M. Barber (Gordonsville, VA)
Assignee: PBM Nutritionals, LLC
A23L33/40A23L33/12A23L33/125A23L33/15A23L33/19A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,342,843
App. No.
18/504,043
Granted
Jul 1, 2025
Kind
B2
Abstract

A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.

Claims (16)

1. An infant formula for term infants comprising:

one or a plurality of protein components such that the total amount of protein is from about 12 g to about 19 g per reconstituted liter (RL);

one or more carbohydrate components such that the total amount of carbohydrates is from about 60 g to about 85 g per RL;

one or more human milk oligosaccharides present in the infant formula in an amount of from about 0.2 g to about 5.0 g per RL, wherein the one or more human milk oligosaccharides are selected from fucosyllactose, 2′FL, 3FL, Lacto-N-fucopentaose I (LNFP I), LNFP II, LNFP III, LNFP V, and mixtures thereof;

phospholipids in an amount of from about 300 mg to about 800 mg per RL;

phosphatidylcholine in an amount of from about 10 mg to about 300 mg per RL;

sphingomyelin in an amount of from about 20 mg to about 400 mg per RL;

one or a plurality of fat components such that the total amount of fat in the infant formula is from about 25 g to about 45 g per RL;

arachidonic acid in an amount of from about 75 mg to about 275 mg per RL;

docosahexaenoic acid in an amount of from about 37 mg to about 180 mg per RL; and

linoleic acid in and amount of from about 4500 mg to about 9500 mg per RL,

wherein the infant formula comprises a milk fat globule membrane component.

2. The infant formula of claim 1 , wherein the milk fat globule membrane component is derived from a whey protein concentrate.

3. The infant formula of claim 2 , wherein the milk fat globule component has a protein content of at least about 60% by weight of the milk fat globule component.

4. The infant formula of claim 3 , wherein the milk fat globule component has a lactose content of not more than about 10% by weight of the milk fat globule component.

5. The infant formula of claim 1 , wherein the one or more human milk oligosaccharides consists of 2′FL.

Assignments (2)
SECURITY INTEREST Recorded May 1, 2026
From: L. PERRIGO COMPANY; PBM NUTRITIONALS, LLC; RANIR, LLC; PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY COMPANY
To: JPMORGAN CHASE BANK N.A.
Reel/Frame 074541/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2023
From: MIKLUS, MICHAEL BERNARD; WITTKE, ANJA MONIKA; PRIETO, PEDRO ANTONIO; BARBER, CYNTHIA M.
To: PBM NUTRITIONALS, LLC
Reel/Frame 065804/0428 →
Continuity (3)
Continuation 16910775 · Jun 24, 2020
Provisional Application 62865874 · Jun 24, 2019
Related Publication 20240251838A1 · Aug 1, 2024
References Cited (10)
US 20070098849A1 · Barrett-Reis · 2007 [cited by examiner]
US 20080003330A1 · Rueda · 2008 [cited by examiner]
US 20120171165A1 · Buck · 2012 [cited by examiner]
US 20160309769A1 · De Castro · 2016 [cited by examiner]
US 20160331017A1 · De Castro · 2016 [cited by examiner]
Brenna, J. T., Varamini, B., Jensen, R. G., Diersen-Schade, D. A., Boettcher, J. A., & Arterburn, L. M. (2007). Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. The American journal of… [cited by examiner]
Andreas, N. J., Kampmann, B., & Le-Doare, K. M. (2015). Human breast milk: A review on its composition and bioactivity. Early human development, 91(11), 629-635. (Year: 2015). [cited by examiner]
Dewettinck, K., Rombaut, R., Thienpont, N., Le, T. T., Messens, K., & Van Camp, J. (2008). Nutritional and technological aspects of milk fat globule membrane material. International dairy journal, 18(5), 436-457. (Year:… [cited by examiner]
Mills, S., Ross, R. P., Hill, C., Fitzgerald, G. F., & Stanton, C. (2011). Milk intelligence: Mining milk for bioactive substances associated with human health. International dairy journal, 21(6), 377-401. (Year: 2011). [cited by examiner]
Brink, L. R., Gueniot, J. P., & Lönnerdal, B. (2019). Effects of milk fat globule membrane and its various components on neurologic development in a postnatal growth restriction rat model. The Journal of Nutritional Bio… [cited by examiner]